{"id":"gefitinib-or-docetaxel","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Diarrhea (Gefitinib)"},{"rate":"40-50","effect":"Rash/acneiform dermatitis (Gefitinib)"},{"rate":"15-20","effect":"Nausea (Gefitinib)"},{"rate":"75-80","effect":"Neutropenia (Docetaxel)"},{"rate":"75-80","effect":"Alopecia (Docetaxel)"},{"rate":"50-60","effect":"Peripheral neuropathy (Docetaxel)"},{"rate":"40-50","effect":"Fatigue (Docetaxel)"}]},"_chembl":{"chemblId":"CHEMBL939","moleculeType":"Small molecule","molecularWeight":"446.91"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Gefitinib selectively inhibits the intracellular tyrosine kinase domain of EGFR, blocking downstream signaling pathways (MAPK and PI3K/AKT) that drive cell proliferation and survival in EGFR-mutant cancers. Docetaxel binds to and stabilizes microtubules, preventing their depolymerization and causing mitotic arrest and apoptosis in rapidly dividing cells. These are distinct mechanisms often used sequentially or in combination for non-small cell lung cancer treatment.","oneSentence":"Gefitinib is an EGFR tyrosine kinase inhibitor that blocks epidermal growth factor receptor signaling to inhibit cancer cell proliferation, while Docetaxel is a microtubule-stabilizing taxane that prevents cell division.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:47:15.313Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer with EGFR mutations (Gefitinib)"},{"name":"Metastatic non-small cell lung cancer (Docetaxel)"},{"name":"Breast cancer (Docetaxel)"},{"name":"Prostate cancer (Docetaxel)"}]},"trialDetails":[{"nctId":"NCT02788201","phase":"PHASE2","title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-27","conditions":"Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms","enrollment":8},{"nctId":"NCT04115410","phase":"","title":"PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study","status":"UNKNOWN","sponsor":"Sungkyunkwan University","startDate":"2020-07-01","conditions":"Carcinoma, Non-Small-Cell Lung, Immune-Related Adverse Events","enrollment":4724},{"nctId":"NCT02179671","phase":"PHASE2","title":"Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-07-25","conditions":"Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)","enrollment":32},{"nctId":"NCT02326285","phase":"PHASE2, PHASE3","title":"Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB","status":"TERMINATED","sponsor":"AIO-Studien-gGmbH","startDate":"2015-11","conditions":"Non-squamous Non-small Cell Lung Cancer Stage II, Non-squamous Non-small Cell Lung Cancer Stage IIIA, Non-squamous Non-small Cell Lung Cancer Stage IIIB","enrollment":1},{"nctId":"NCT00231465","phase":"PHASE2","title":"Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2003-07","conditions":"Non-Small Cell Lung Cancer","enrollment":44},{"nctId":"NCT00086957","phase":"PHASE1, PHASE2","title":"Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2004-01","conditions":"Breast Cancer","enrollment":31},{"nctId":"NCT02031601","phase":"PHASE4","title":"Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2014-01","conditions":"Non-Small-Cell Lung Cancer","enrollment":250},{"nctId":"NCT02701231","phase":"NA","title":"Low-frequency Rotating Magnetic System Combined With Systemic Anti-tumor Therapy for Advanced Lung Cancer","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2015-11","conditions":"Lung Neoplasms","enrollment":200},{"nctId":"NCT00062270","phase":"PHASE1, PHASE2","title":"Neoadjuvant Chemoradiotherapy With or Without Gefitinib in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2003-05","conditions":"Lung Cancer","enrollment":""},{"nctId":"NCT00088907","phase":"PHASE3","title":"Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-08","conditions":"Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer","enrollment":270},{"nctId":"NCT00536107","phase":"PHASE4","title":"Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2007-10","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":14},{"nctId":"NCT00020709","phase":"PHASE3","title":"Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-06","conditions":"Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer","enrollment":840},{"nctId":"NCT01755923","phase":"PHASE2","title":"Gefitinib or Docetaxel as Second Line Therapy for Wild-type Epidermal Growth Factor Receptor (EGFR) NSCLC","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2012-12","conditions":"Non-small Cell Lung Cancer","enrollment":60},{"nctId":"NCT01746277","phase":"PHASE2","title":"Study of Chemotherapy Sequenced by or Combined With EGFR-TKIs for NSCLC Patients Failed to EGFR-TKIs Therapy","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2012-10","conditions":"Non Small Cell Lung Cancer","enrollment":60},{"nctId":"NCT00048087","phase":"PHASE2","title":"Iressa/Docetaxel in Non-Small-Cell Lung Cancer","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2002-08","conditions":"Non-small Cell Lung Cancer","enrollment":""},{"nctId":"NCT00478049","phase":"PHASE3","title":"Iressa as Second Line Therapy in Advanced NSCLC-Asia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-09","conditions":"NSCLC","enrollment":163},{"nctId":"NCT00076388","phase":"PHASE3","title":"Iressa Versus Docetaxel (Taxotere)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-02","conditions":"Non-Small-Cell Lung Carcinoma","enrollment":1440},{"nctId":"NCT00242762","phase":"PHASE2","title":"ZD1839 (IRESSA™) in Combination With Docetaxel & Cisplatin in Subjects With Metastatic Head & Neck Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-07","conditions":"Head and Neck Cancer","enrollment":36},{"nctId":"NCT00198393","phase":"PHASE2","title":"Randomized Phase 2 Study of 3 Therapeutic Modalities in PS 2/3 Patients With NSCLC Stage IIIB/IV","status":"COMPLETED","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2004-11","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":126},{"nctId":"NCT00319800","phase":"PHASE2","title":"Second-Line Irinotecan or Gefitinib in Docetaxel Pretreated NSCLC","status":"UNKNOWN","sponsor":"Gachon University Gil Medical Center","startDate":"2006-02","conditions":"Non-Small Cell Lung Cancer","enrollment":50},{"nctId":"NCT00052169","phase":"PHASE2","title":"Therapy With Docetaxel and ZD1839 for Patients Who Have Advanced Breast Cancer","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"2003-01","conditions":"Breast Neoplasms","enrollment":33},{"nctId":"NCT00319618","phase":"PHASE2","title":"Combination Weekly Taxotere™ With Iressa™ /Placebo in Metastatic Breast Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-06","conditions":"Metastatic Breast Cancer","enrollment":66},{"nctId":"NCT00252707","phase":"PHASE3","title":"Iressa 2nd Line Phase III Study in Japan","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-09","conditions":"Non-Small Cell Lung Cancer","enrollment":484}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":29873,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Gefitinib or Docetaxel","genericName":"Gefitinib or Docetaxel","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gefitinib is an EGFR tyrosine kinase inhibitor that blocks epidermal growth factor receptor signaling to inhibit cancer cell proliferation, while Docetaxel is a microtubule-stabilizing taxane that prevents cell division. Used for Non-small cell lung cancer with EGFR mutations (Gefitinib), Metastatic non-small cell lung cancer (Docetaxel), Breast cancer (Docetaxel).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}